Last updated: September 22, 2026
Idecabtagene vicleucel, marketed as Abecma, is a BCMA-directed autologous CAR-T therapy developed by Bristol Myers Squibb and 2seventy bio for relapsed or refractory multiple myeloma. Its commercial trajectory has been shaped by three forces: expansion into earlier treatment lines, strong competition from ciltacabtagene autoleucel, and the cost and complexity of manufacturing patient-specific cell therapies.
Bristol Myers Squibb reported Abecma net product sales of $334 million in 2024, down from $472 million in 2023 and $356 million in 2022.[1] The decline occurred despite a broader U.S. label because Carvykti gained share in the same BCMA CAR-T market and Abecma faced manufacturing and treatment-center capacity constraints.
What is idecabtagene vicleucel and how does Abecma work?
Idecabtagene vicleucel is an autologous CAR-T product that genetically modifies a patient’s T cells to recognize B-cell maturation antigen, or BCMA, on malignant plasma cells.
| Product |
Active therapy |
Target |
Company |
| Abecma |
Idecabtagene vicleucel |
BCMA |
Bristol Myers Squibb and 2seventy bio |
| Carvykti |
Ciltacabtagene autoleucel |
BCMA |
Janssen, now Johnson & Johnson, and Legend Biotech |
| Tecelra |
Afamitresgene autoleucel |
MAGE-A4 |
Adaptimmune |
| Breyanzi |
Lisocabtagene maraleucel |
CD19 |
Bristol Myers Squibb |
Abecma is manufactured from the patient’s own leukapheresis material. The process includes T-cell selection, activation, viral-vector transduction, expansion, quality control and reinfusion after lymphodepleting chemotherapy. The patient-specific manufacturing chain creates higher operational barriers than those associated with conventional drugs or off-the-shelf biologics.
What is the FDA status and approved use of Abecma?
The FDA approved Abecma on March 26, 2021, for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.[2]
In April 2024, the FDA expanded the indication to adults with relapsed or refractory multiple myeloma after at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor, when the disease is refractory to lenalidomide.[3]
The principal FDA milestones are:
| Date |
Regulatory event |
| March 26, 2021 |
Initial FDA approval after at least four prior lines |
| 2021 |
Commercial launch in the United States |
| 2022 |
Additional international approvals and commercial expansion |
| April 2024 |
U.S. expansion into earlier-line, lenalidomide-refractory disease |
| 2024 |
FDA labeling included boxed-warning language concerning T-cell malignancies after CAR-T treatment |
The earlier-line approval materially increases the addressable population. It also places Abecma in direct competition with Carvykti in a treatment setting where physicians have more alternatives and clinical differentiation is more important.
How much revenue does Abecma generate?
Abecma revenue peaked in 2023 before declining in 2024.
| Fiscal year |
BMS-reported Abecma sales |
Year-over-year change |
| 2021 |
Approximately $164 million |
New launch |
| 2022 |
$356 million |
Approximately 117% |
| 2023 |
$472 million |
Approximately 33% |
| 2024 |
$334 million |
Approximately negative 29% |
Sources: Bristol Myers Squibb annual reports and securities filings.[1,4]
The 2024 decline is commercially significant because it followed an FDA label expansion. The result indicates that the new indication did not immediately offset competitive pressure, site capacity restrictions and physician preference for Carvykti in some treatment settings.
Abecma also contributes economically to 2seventy bio through its collaboration with Bristol Myers Squibb. The companies share economics under their strategic agreement, with BMS responsible for major commercial and manufacturing functions and 2seventy retaining an economic interest in the product.[5]
What is the Abecma revenue outlook through 2030?
The near-term trajectory depends on whether the 2024 label expansion produces sustained uptake in second- and third-line treatment.
Base-case outlook
A reasonable base case is stabilization followed by moderate growth if:
- additional treatment centers become operational;
- manufacturing turnaround times improve;
- the earlier-line indication generates more referrals;
- Abecma maintains a differentiated position in patients previously exposed to lenalidomide;
- payer coverage remains favorable for hospital-based CAR-T administration.
Under this scenario, Abecma could recover toward or above its 2023 sales level, but the product is unlikely to achieve unchallenged market leadership.
Downside case
The principal downside is continued displacement by Carvykti, particularly in earlier-line disease. Carvykti has shown strong efficacy in the CARTITUDE-4 study, including a progression-free survival advantage over standard regimens in patients with lenalidomide-refractory multiple myeloma after one to three prior lines.[6]
A downside scenario would include:
- persistent Carvykti share gains;
- shorter treatment sequencing before BCMA CAR-T;
- manufacturing delays that cause physicians to choose another treatment;
- limited adoption outside major academic centers;
- increased scrutiny of CAR-T safety and long-term monitoring.
Upside case
The upside case depends on higher manufacturing throughput and better positioning in the growing multiple myeloma population. Earlier-line use expands the commercial pool substantially because multiple myeloma is a chronic, relapsing disease with a large population receiving successive therapies.
The principal commercial constraint is not only disease prevalence. It is the percentage of patients who are fit for CAR-T, have adequate performance status, can receive lymphodepletion, can reach an authorized treatment center and can tolerate the manufacturing wait.
How does Abecma compare with Carvykti?
Carvykti is the most important competitive threat to Abecma. Both products target BCMA and require autologous manufacturing, but their clinical profiles and commercial momentum differ.
| Category |
Abecma |
Carvykti |
| Active ingredient |
Idecabtagene vicleucel |
Ciltacabtagene autoleucel |
| Target |
BCMA |
BCMA |
| Initial U.S. approval |
2021 |
2022 |
| Earlier-line use |
Expanded in 2024 |
Expanded in 2024 |
| Key developers |
BMS and 2seventy bio |
J&J and Legend Biotech |
| Manufacturing model |
Autologous |
Autologous |
| List price at launch |
Approximately $419,500 |
Approximately $465,000 |
| Main risk |
Competitive share loss and manufacturing capacity |
Manufacturing capacity, safety monitoring and supply constraints |
Carvykti uses a CAR design with two BCMA-binding domains, while Abecma uses a single-chain variable fragment-based construct. Cross-trial comparisons do not establish definitive superiority, but the commercial market has treated Carvykti as a strong efficacy competitor.
Abecma retains advantages from earlier market entry, established treatment-center experience and an expanded label. Carvykti has benefited from rapid uptake, strong efficacy data and increasing use in earlier lines.
What patents protect idecabtagene vicleucel?
Abecma is a biologic, so its U.S. regulatory protection is not organized through the small-molecule Orange Book. The relevant sources are biologic exclusivity under the Biologics Price Competition and Innovation Act, patent families covering CAR constructs and BCMA-targeting technology, vector and cell-engineering methods, manufacturing processes, and potentially formulation or cryopreservation techniques.
The principal U.S. regulatory protection is:
| Protection |
Key date or status |
| FDA approval |
March 26, 2021 |
| Reference-product biologic exclusivity |
Generally 12 years from first licensure |
| Earliest statutory biosimilar approval opportunity |
Approximately March 26, 2033, subject to applicable law |
| Orphan-drug protection |
May apply to the approved multiple myeloma indication, but does not block all competing products or all later-line therapies |
| Orange Book listing |
No conventional Orange Book listing for Abecma |
| Purple Book relevance |
Biologic reference-product and biosimilar status are tracked through the Purple Book framework |
The 12-year BPCIA period is not the same as patent expiry. Patent families may extend beyond the exclusivity period, while some claims may expire earlier or be vulnerable to validity and infringement challenges.
The highest-value intellectual-property barriers are likely to be manufacturing know-how, viral-vector production, release testing, cell-processing controls and process consistency. Those barriers can delay competitors even when a competing product does not infringe the same composition claims.
When does Abecma lose exclusivity?
The key federal biologic-exclusivity date is March 26, 2033, based on the product’s first U.S. licensure in 2021.[2] That date does not guarantee immediate biosimilar competition.
A biosimilar applicant may file an application under the BPCIA before the reference-product exclusivity period ends, but FDA approval cannot take effect before the statutory exclusivity period expires. Patent litigation, FDA review timing, manufacturing readiness and commercial launch decisions can extend the period before meaningful competition.
Unlike a conventional prescription drug, Abecma does not have a standard Orange Book patent-and-exclusivity framework. A complete entry analysis requires review of the relevant patent families, patent-term adjustments, terminal disclaimers, patent challenges and any settlement agreements.
What biosimilar and generic entry risks exist for Abecma?
Traditional generic entry is not available because Abecma is a biologic administered as a patient-specific cellular product. The relevant future competitor is a biosimilar or other follow-on cell therapy, not an Abbreviated New Drug Application product.
Biosimilar risk is lower in the near term than for conventional biologics because a follow-on CAR-T product must replicate:
- the CAR sequence and expression profile;
- cell composition and potency;
- transduction and expansion controls;
- release specifications;
- lymphodepletion and administration procedures;
- long-term safety monitoring;
- manufacturing reliability at commercial scale.
The practical commercial risk may arrive first from another branded BCMA therapy, a bispecific antibody or a next-generation CAR-T product rather than from a biosimilar.
What treatment alternatives compete with Abecma?
The competitive landscape includes BCMA CAR-T therapies, BCMA bispecific antibodies and non-BCMA regimens.
BCMA-directed competitors
Carvykti is the direct CAR-T competitor. Its commercial performance has placed pressure on Abecma in both heavily pretreated and earlier-line disease.
BCMA bispecific antibodies
Elranatamab and teclistamab offer off-the-shelf administration and avoid the manufacturing wait associated with autologous CAR-T. They can be used in patients who are not suitable for CAR-T or whose disease progresses while cells are being manufactured.
Their disadvantages include repeated dosing, infection risk, hypogammaglobulinemia and the need for ongoing treatment. CAR-T products offer a one-time treatment model, which can be attractive to patients, physicians and payers despite higher upfront cost.
Conventional multiple myeloma regimens
Proteasome inhibitors, immunomodulatory agents, anti-CD38 antibodies, antibody-drug conjugates and chemotherapy remain part of the treatment sequence. The earlier Abecma moves in the treatment pathway, the more it competes with established combination regimens rather than serving only as a last-line option.
What is the financial exposure for Bristol Myers Squibb and 2seventy bio?
For Bristol Myers Squibb, Abecma is a strategic growth product but remains small relative to the company’s largest brands. The 2024 revenue decline reduced its contribution to BMS’s growth portfolio.
For 2seventy bio, Abecma is far more material. The company’s business model has been heavily concentrated around its economic interest in the product. A sustained decline in Abecma demand creates greater financial pressure for 2seventy than for BMS because 2seventy has fewer commercial products to offset lost revenue.
The principal value drivers are:
- Abecma market share in earlier-line disease.
- Manufacturing throughput and turnaround time.
- Capacity and productivity at authorized treatment centers.
- Relative clinical outcomes versus Carvykti.
- Adoption of CAR-T before bispecific antibody therapy.
- Pricing and reimbursement for inpatient and outpatient administration.
- Long-term safety data and regulatory treatment of CAR-T risks.
What is the current litigation and settlement status?
No major publicly reported Abecma Paragraph IV litigation framework exists because Abecma is not an Orange Book-listed small-molecule drug. Any future patent dispute would more likely involve BPCIA patent procedures, patent litigation over CAR architecture or manufacturing technology, or disputes involving upstream licensors and vector or cell-engineering patents.
The commercial partnership between BMS and 2seventy is more important to near-term economics than a generic settlement. The collaboration governs development, commercialization and profit allocation, while BMS controls much of the commercial infrastructure.
How strong is the Abecma patent and manufacturing estate?
Abecma has a stronger practical barrier than its regulatory exclusivity date alone suggests. The product requires a coordinated manufacturing system that includes patient identity controls, chain of custody, specialized cell processing, quality release and trained clinical sites.
Patent strength is likely to be strongest where claims cover:
- BCMA-specific CAR constructs;
- vector design and transduction methods;
- T-cell activation and expansion;
- cell composition and potency;
- cryopreservation;
- manufacturing and release methods.
Patent risk is higher for broad platform claims that may face validity challenges or design-around strategies. Manufacturing know-how is harder to replicate but is also less visible in public patent records.
Key Takeaways
- Abecma generated $334 million in BMS-reported sales in 2024, down from $472 million in 2023.
- The April 2024 FDA label expansion moved Abecma into earlier-line, lenalidomide-refractory multiple myeloma.
- Carvykti is the principal commercial and clinical competitor.
- The earliest statutory U.S. biologic-exclusivity date is approximately March 26, 2033.
- Orange Book patent analysis does not apply in the conventional small-molecule sense.
- Near-term competition will come mainly from Carvykti and BCMA bispecific antibodies, not traditional generics.
- Manufacturing capacity, turnaround time and treatment-center access are major value drivers.
- 2seventy bio has substantially greater financial exposure to Abecma than Bristol Myers Squibb.
- The product’s practical barriers include manufacturing know-how, specialized infrastructure and long-term safety requirements.
FAQs
Is Abecma a biosimilar or a biologic?
Abecma is an autologous biologic cell therapy and CAR-T product. It is not a biosimilar or a conventional small-molecule drug.
Can Abecma be used before Carvykti?
Yes. Treatment sequencing is determined by the approved indications, patient characteristics, prior therapy, physician judgment and payer requirements. Both products compete in earlier-line multiple myeloma after their respective label expansions.
Does Abecma have an Orange Book patent?
No conventional Orange Book listing applies because Abecma is regulated as a biologic. Patent protection must be assessed through patent records, BPCIA procedures and relevant licensing or collaboration agreements.
Why did Abecma sales decline in 2024 despite a broader FDA label?
The decline reflects competitive pressure from Carvykti, treatment-center and manufacturing constraints, and the time required for an earlier-line indication to affect patient flow and commercial demand.
Are bispecific antibodies a serious threat to Abecma?
Yes. Bispecific antibodies are available off the shelf and avoid the manufacturing wait for autologous CAR-T. Their need for repeated administration and their infection-related safety profile create tradeoffs that preserve a role for one-time CAR-T treatment.
References
-
Bristol Myers Squibb. (2025). 2024 annual report. Bristol Myers Squibb.
-
U.S. Food and Drug Administration. (2021). FDA approves idecabtagene vicleucel for multiple myeloma. FDA.
-
U.S. Food and Drug Administration. (2024). Abecma prescribing information. FDA.
-
Bristol Myers Squibb. (2024). 2023 annual report. Bristol Myers Squibb.
-
2seventy bio, Inc. (2024). Annual report and collaboration disclosures. 2seventy bio.
-
San-Miguel, J., Dhakal, B., Yong, K., et al. (2023). Ciltacabtagene autoleucel or standard care in lenalidomide-refractory multiple myeloma. The New England Journal of Medicine, 389(4), 335-347.
